| Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure LB Arendse, AHJ Danser, M Poglitsch, RM Touyz, JC Burnett, ... Pharmacological reviews 71 (4), 539-570, 2019 | 318 | 2019 |
| Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity M Vanaerschot, JM Murithi, CFA Pasaje, S Ghidelli-Disse, L Dwomoh, ... Cell chemical biology 27 (7), 806-816. e8, 2020 | 61 | 2020 |
| Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities LB Arendse, S Wyllie, K Chibale, IH Gilbert ACS Infectious Diseases 7 (3), 518-534, 2021 | 45 | 2021 |
| An expanded, unified substrate recognition site map for mammalian cytochrome P450s: analysis of molecular interactions between 15 mammalian CYP450 isoforms and 868 substrates A Zawaira, LY Ching, L Coulson, J Blackburn, Y Chun Wei Current drug metabolism 12 (7), 684-700, 2011 | 36 | 2011 |
| Molecular basis for multiple omapatrilat binding sites within the ACE C-domain: implications for drug design GE Cozier, LB Arendse, SL Schwager, ED Sturrock, KR Acharya Journal of Medicinal Chemistry 61 (22), 10141-10154, 2018 | 24 | 2018 |
| Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb) ED Sturrock, L Lubbe, GE Cozier, SLU Schwager, AT Arowolo, ... Biochemical Journal 476 (10), 1553-1570, 2019 | 20 | 2019 |
| Structural Basis for Inhibitor Potency and Selectivity of Plasmodium falciparum Phosphatidylinositol 4-Kinase Inhibitors S Fienberg, CJ Eyermann, LB Arendse, GS Basarab, JA McPhail, ... ACS Infectious Diseases 6 (11), 3048-3063, 2020 | 19 | 2020 |
| On the deduction and analysis of singlet and two-state gating-models from the static structures of mammalian CYP450 A Zawaira, L Coulson, M Gallotta, O Karimanzira, J Blackburn Journal of structural biology 173 (2), 282-293, 2011 | 19 | 2011 |
| Selective inhibition of the C-domain of ACE (angiotensin-converting enzyme) combined with inhibition of NEP (Neprilysin): a potential new therapy for hypertension R Alves-Lopes, AC Montezano, KB Neves, A Harvey, FJ Rios, DS Skiba, ... Hypertension 78 (3), 604-616, 2021 | 14 | 2021 |
| New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and … PM Cheuka, L Centani, LB Arendse, S Fienberg, L Wambua, SS Renga, ... ACS Infectious Diseases 7 (1), 34-46, 2020 | 12 | 2020 |
| Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution LB Arendse, JM Blackburn Scientific Reports 8 (1), 11876, 2018 | 12 | 2018 |
| Exhaustive computational search of ionic-charge clusters that mediate interactions between mammalian cytochrome P450 (CYP) and P450-oxidoreductase (POR) proteins A Zawaira, M Gallotta, N Beeton-Kempen, L Coulson, P Marais, M Kuttel, ... Computational biology and chemistry 34 (1), 42-52, 2010 | 12 | 2010 |
| The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages LB Arendse, JM Murithi, T Qahash, CFA Pasaje, LC Godoy, S Dey, ... Science translational medicine 14 (667), eabo7219, 2022 | 11 | 2022 |
| Combining in silico protein stability calculations with structure-function relationships to explore the effect of polymorphic variation on cytochrome P450 drug metabolism L Arendse, T L Blundell, J Blackburn Current Drug Metabolism 14 (7), 745-763, 2013 | 6 | 2013 |
| Probing the requirements for dual angiotensin-converting enzyme C-domain selective/neprilysin inhibition LB Arendse, GE Cozier, CJ Eyermann, GS Basarab, SL Schwager, ... Journal of Medicinal Chemistry 65 (4), 3371-3387, 2022 | 5 | 2022 |
| Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38 JF Armstrong, B Campo, SPH Alexander, LB Arendse, X Cheng, ... British Journal of Pharmacology 180 (15), 1899-1929, 2023 | 4 | 2023 |
| Developing kinase inhibitors for malaria: an opportunity or liability? KSP Mogwera, K Chibale, LB Arendse Trends In Parasitology, 2023 | 2 | 2023 |
| Exploring the effects of polymorphic variation on the stability and function of human cytochrome P450 enzymes in silico and in vitro LB Arendse | 1 | 2014 |
| INHIBITION OF ACE C-DOMAIN AND NEPRILYSIN AS A NEW THERAPY IN HYPERTENSION R Alves-Lopes, A Montezano, K Neves, A Harvey, F Rios, L Arendse, ... Journal of Hypertension 39, e385, 2021 | | 2021 |
| MUK Patent Application WGB (112485479 R Lovers Walk, JM Blackburn, N Beeton-Kempen, LB Coulson Methods in Molecular Biology 12, 56, 2006 | | 2006 |
